文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

雷珠单抗作为早产儿视网膜病变首选治疗:解剖学结局及影响因素

Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
PubMed 文献 · Ophthalmology · 2017-04-12

回顾性病例系列纳入145例1型早产儿视网膜病变患儿的283只眼,以雷珠单抗玻璃体腔内注射(0.25 mg/0.025 ml)作为首选治疗。末次随访时278只眼(98.2%)视网膜在位,5只眼(1.8%)发生视网膜脱离。分类树模型显示,胎龄≤29.5周者注射后复发可能性高于胎龄>29.5周者(61.6% vs 29.6%);胎龄≤29.5周者中,诊断为II区2期+病变者复发可能性低于其他患者(37.9% vs 80%)。

要点

  • 145例1型早产儿视网膜病变患儿283只眼以雷珠单抗玻璃体腔内注射(0.25 mg/0.025 ml)为首选治疗。
  • 266只眼(94.0%)治疗后呈阳性反应,其中139只眼(48.6%)消退无复发、127只眼(44.9%)消退后复发。
  • 胎龄≤29.5周者注射后复发可能性高于胎龄>29.5周者(61.6% vs 29.6%)。

原文

PURPOSE: To investigate the anatomic outcomes and influencing factors of ranibizumab in the treatment of retinopathy of prematurity (ROP). DESIGN: Retrospective case series. PARTICIPANTS: A total of 283 eyes of 145 patients with type 1 ROP treated with intravitreal injection of ranibizumab (IVR) as primary treatment. METHODS: Retrospective review of infants who were diagnosed with type 1 ROP and accepted IVR (0.25 mg/0.025 ml) as primary treatment from January 2012 to August 2015. The anatomic outcomes and the influencing factors were analyzed. MAIN OUTCOME MEASURES: Anatomic outcomes of ROP eyes after IVR and the influencing factors. RESULTS: A total of 283 eyes of 145 patients were included in this study. There were a total of 266 eyes (94.0%) in the positive response group and 17 eyes (6.0%) in the negative/no response group after IVR. Within the positive response group, 139 eyes (48.6%) were in the regression without reactivation subgroup, and 127 eyes (44.9%) were in the regression with reactivation subgroup. A total of 152 eyes received additional laser or surgical treatment. At the last visit, 278 eyes (98.2%) had attached retinas, and 5 eyes (1.8%) had retinal detachment. A classification tree model showed that for patients with gestational age (GA) ≤29.5 weeks, the possibility of experiencing reactivation after IVR is higher than that of those with GA >29.5 weeks (61.6% vs. 29.6%). Moreover, for patients with GA ≤29.5 weeks, those diagnosed with zone II stage 2+ ROP have a lower possibility of experiencing reactivation than other patients (37.9% vs. 80%). CONCLUSIONS: Intravitreal injection of ranibizumab seemed to be effective in treating patients with ROP. After treatment, there were primarily 3 different outcomes. Our predictive tree model is helpful for ophthalmologists to evaluate the risk of reactivation.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Huang Q, Zhang Q, Fei P, et al. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors. Ophthalmology. 2017. PMID: 28412066. doi:10.1016/j.ophtha.2017.03.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。